---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-020094"
form_type: "8-K"
ticker: "PVLA"
cik: "0001583648"
company_name: "PALVELLA THERAPEUTICS, INC."
filed_at: "2023-07-18T23:59:59+00:00"
generated_at: "2026-06-13T07:02:01.506241+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Pieris terminates AstraZeneca deal, cuts 70% workforce, explores strategic alternatives

## Summary
- AstraZeneca terminates R&D collaboration effective Oct 15, 2023 due to non-clinical safety findings in elarekibep toxicology study.
- Workforce reduced by ~70%; expects ~$3.4M severance costs in Q3 2023.
- Cash, equivalents, investments ~$54.9M as of June 30, 2023 (preliminary).
- Pieris hires Stifel as financial advisor to explore strategic alternatives including M&A, licensing, or sale.
- Focus shifted to advancing cinrebafusp alfa, PRS-220, PRS-400; no assurance of transaction outcome.

## SEC filing metadata
- accession: 0001437749-23-020094
- form_type: 8-K
- ticker: PVLA
- cik: 0001583648
- company_name: PALVELLA THERAPEUTICS, INC.
- filed_at: 2023-07-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.02, 2.02, 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583648/000143774923020094/0001437749-23-020094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583648/000143774923020094/pirs20230705_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-020094
- JSON: https://secwatch.observer/filing/0001437749-23-020094.json
- Plain text: https://secwatch.observer/filing/0001437749-23-020094.txt

## Key facts
- Restructurings & Charges
  PALVELLA THERAPEUTICS, INC. announced a restructuring with charges of approximately $3.4 million (approximately 70%).
  - Type: restructuring
  - Charge: approximately $3.4 million
  - Headcount: approximately 70%
  source text: on July 17, 2023, the Board of Directors of the Company approved a reduction in force of the Company's workforce by approximately 70% to be substantially completed in the fourth quarter of 2023 (the "Workplace Reduction"). As a result of the Workplace Reduction, the Company expects to incur estimated severance and other employee termination-related costs of approximately $3.4 million in the third quarter 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583648/000143774923020094/0001437749-23-020094-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.